321 reports of this reaction
1.4% of all CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES reports
#20 most reported adverse reaction
SUICIDAL IDEATION is the #20 most commonly reported adverse reaction for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, manufactured by Jazz Pharmaceuticals, Inc.. There are 321 FDA adverse event reports linking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES to SUICIDAL IDEATION. This represents approximately 1.4% of all 22,248 adverse event reports for this drug.
Patients taking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES who experience suicidal ideation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUICIDAL IDEATION is a less commonly reported adverse event for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, but still significant enough to appear in the safety profile.
In addition to suicidal ideation, the following adverse reactions have been reported for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES:
The following drugs have also been linked to suicidal ideation in FDA adverse event reports:
SUICIDAL IDEATION has been reported as an adverse event in 321 FDA reports for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUICIDAL IDEATION accounts for approximately 1.4% of all adverse event reports for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, making it a notable side effect.
If you experience suicidal ideation while taking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.